Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, small-cap biotech Repligen (NASDAQ: RGEN ) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Repligen and see what CAPS investors are saying about the stock right now.
Repligen facts
| Headquarters (founded) | Waltham, Mass. (1981) |
| Market Cap | $240.2 million |
| Industry | Biotechnology |
| Trailing-12-Month Revenue | $65.9 million |
| Management | CEO Dr. Walter Herlihy |
| Trailing-12-Month Return on Equity | 19.6% |
| Cash/Debt | $47.9 million / $0 |
| Competitors | Bio-Rad Laboratories |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 98% of the 333 members who have rated Repligen believe the stock will outperform the S&P 500 going forward.
Just yesterday, one of those Fools, All-Star zzlangerhans, succinctly summed up the Repligen bull case for our community:
I missed the bump in Repligen's share price in the spring because I set an outperform threshold of 6 that never quite clicked. The stock has been pulling back over the last month but I still like the growing bioprocessing revenues, courtesy of the excellent acquisition of Novozymes Biopharma Sweden AB in 2011. Repligen still has to outgrow a well-deserved reputation for futility but if they can successfully transition from drug development into products and services there's still a lot of potential for share price appreciation.
If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a perfect five-star rating, Repligen may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
No comments:
Post a Comment